
Jihane Khalife

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7344068/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>RUNX1</i> Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures. Journal of Clinical Oncology, 2012, 30, 3109-3118.	1.6	242
2	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia, 2021, 35, 189-200.	7.2	56
3	Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood, 2018, 131, 741-745.	1.4	54
4	SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. Journal of Clinical Investigation, 2014, 124, 1512-1524.	8.2	52
5	Targeting the RAS/MAPK pathway with <i>miR-181a</i> in acute myeloid leukemia. Oncotarget, 2016, 7, 59273-59286.	1.8	50
6	Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. OncoImmunology, 2018, 7, e1486948.	4.6	41
7	MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. JCI Insight, 2019, 4, .	5.0	33
8	In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline. Haematologica, 2013, 98, e92-e94.	3.5	13
9	Effects of Ascorbic Acid on Tax, NF-κB and MMP-9 in Human T-cell Lymphotropic Virus Type 1 Positive Malignant T-Lymphocytes. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 237-244.	1.7	0